本帖最后由 老马 于 2012-1-13 21:20 编辑 & n: @4 U) [# u: J
( c, t: P1 ?0 o1 B爱必妥和阿瓦斯丁的比较
8 @" _* L9 N; b7 G( o4 m
+ b2 ^! ~* J- e4 X9 bhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/% m3 B' `% \- @! \9 s6 c
8 U7 h1 R5 O5 I' N, u9 G' M9 f" Z
3 x. u7 Q3 N3 E% r
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/0 E/ \- E% n! h/ c4 X) d6 a3 Q
==================================================# }9 A' F* ^4 u
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL): _) Q2 [' s3 a
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
4 K$ Q! Y# r* v; d/ i) BResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
. ]7 N* L( j/ k
|
显身卡
